SCHEMBL6796259

SCHEMBL6796259

O=C(Nc1ccc(NCCc2ccccn2)cc1)c1ccccc1-c1ccc(OCCO)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.50
RAB9A P51151 3/20 0.50
GAA P10253 2/20 0.47
POLB P06746 2/20 0.47
LMNA P02545 2/20 0.47
HTT P42858 2/20 0.47
SMO Q99835 2/20 0.46
MEN1 O00255 3/20 0.46
MAPT P10636 3/20 0.46
KMT2A Q03164 3/20 0.46
ALDH1A1 P00352 1/20 0.45
CA12 O43570 1/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
CA9 Q16790 1/20 0.45
CHRNB2 P17787 2/20 0.44
CHRNB4 P30926 2/20 0.44
CHRNA3 P32297 2/20 0.44
CHRNA4 P43681 2/20 0.44
KDM4E B2RXH2 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6793936 0.93 NPC1 (0.53) NPC1RAB9AGAAPOLBLMNA
SCHEMBL6795010 0.91 RAB9A (0.55) NPC1RAB9AGAAPOLBLMNA
SCHEMBL6794339 0.91 NPC1 (0.47) NPC1RAB9AGAAPOLBLMNA
SCHEMBL6792821 0.90 GAA (0.48) NPC1RAB9AGAAPOLBLMNA
SCHEMBL6793336 0.90 RAB9A (0.65) NPC1RAB9AGAAPOLBLMNA
SCHEMBL6795192 0.90 NPC1 (0.47) NPC1RAB9AGAAPOLBLMNA
SCHEMBL6792178 0.89 MAPT (0.50) NPC1RAB9AGAAPOLBLMNA
SCHEMBL6793719 0.89 SMO (0.49) NPC1RAB9AGAAPOLBLMNA
SCHEMBL6792973 0.89 NPC1 (0.47) NPC1RAB9AGAAPOLBLMNA
SCHEMBL6792042 0.89 NPC1 (0.52) NPC1RAB9AGAAPOLBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-03-25 US disclosed
EP-1326835-A1 BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-07-16 EP disclosed
WO-2002028835-A1 BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-04-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors APOB, APOL1, SCARB1 NPC1 64/4885RAB9A 3707/4885GAA 977/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.